BR9603540A - n-metil-n-((1s)-2-((3s)-3-hidróxl-pirrolidin-1-il)etil)-2,2-difenilacetamida - Google Patents

n-metil-n-((1s)-2-((3s)-3-hidróxl-pirrolidin-1-il)etil)-2,2-difenilacetamida

Info

Publication number
BR9603540A
BR9603540A BR9603540A BR9603540A BR9603540A BR 9603540 A BR9603540 A BR 9603540A BR 9603540 A BR9603540 A BR 9603540A BR 9603540 A BR9603540 A BR 9603540A BR 9603540 A BR9603540 A BR 9603540A
Authority
BR
Brazil
Prior art keywords
diphenylacetamide
pyrrolidin
hydroxy
ethyl
methyl
Prior art date
Application number
BR9603540A
Other languages
English (en)
Inventor
Inge Stein
Klaus Beschmann
Andrew Barber
Steffen Neuenfeld
Holger Beeres
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR9603540A publication Critical patent/BR9603540A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
BR9603540A 1995-08-26 1996-08-23 n-metil-n-((1s)-2-((3s)-3-hidróxl-pirrolidin-1-il)etil)-2,2-difenilacetamida BR9603540A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19531464A DE19531464A1 (de) 1995-08-26 1995-08-26 N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid

Publications (1)

Publication Number Publication Date
BR9603540A true BR9603540A (pt) 1998-05-12

Family

ID=7770485

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9603540A BR9603540A (pt) 1995-08-26 1996-08-23 n-metil-n-((1s)-2-((3s)-3-hidróxl-pirrolidin-1-il)etil)-2,2-difenilacetamida

Country Status (25)

Country Link
US (1) US6060504A (pt)
EP (1) EP0761650B1 (pt)
JP (3) JP5023273B2 (pt)
KR (1) KR100436254B1 (pt)
CN (1) CN1081631C (pt)
AR (1) AR004679A1 (pt)
AT (1) ATE207895T1 (pt)
AU (1) AU716615B2 (pt)
BR (1) BR9603540A (pt)
CA (1) CA2184049C (pt)
CZ (1) CZ287783B6 (pt)
DE (2) DE19531464A1 (pt)
DK (1) DK0761650T3 (pt)
ES (1) ES2165948T3 (pt)
HU (1) HU226667B1 (pt)
MX (1) MX9603606A (pt)
NO (1) NO307048B1 (pt)
PL (1) PL187691B1 (pt)
PT (1) PT761650E (pt)
RU (1) RU2174976C2 (pt)
SI (1) SI0761650T1 (pt)
SK (1) SK282437B6 (pt)
TW (1) TW513407B (pt)
UA (1) UA41978C2 (pt)
ZA (1) ZA967200B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032096A1 (en) * 1997-12-22 1999-07-01 Alza Corporation Novel formulations for the transdermal administration of asimadoline
DE19827633A1 (de) * 1998-04-20 1999-10-21 Merck Patent Gmbh Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
DE10116978A1 (de) * 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
EP2074997A1 (en) * 2002-05-17 2009-07-01 Tioga Pharmaceuticals, Inc. Use of Asimadoline for the treatment of digestive disorders
DE10259245A1 (de) * 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
JP2007509865A (ja) * 2003-10-30 2007-04-19 ティオガ ファーマシュウティカルズ，インコーポレイテッド 神経障害の治療における選択的オピエート受容体調節物質の使用
EP2561870A1 (en) 2007-03-30 2013-02-27 Tioga Pharmaceuticals, Inc. Kappa-Opiate Agonists For The Treatment Of Diarrhea-Predominant and Alternating Irritable Bowel Syndrome
EP2284987B1 (en) * 2009-08-12 2019-02-06 Braun GmbH Method and device for adjusting the frequency of a drive current of an electric motor
CN102946729B (zh) * 2010-04-07 2014-11-05 欧尼斯治疗公司 结晶肽环氧酮免疫蛋白酶体抑制剂
US9675587B2 (en) 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
CN103664727A (zh) * 2013-12-19 2014-03-26 无锡万全医药技术有限公司 一种一锅法制备1-[(3s)-3-羟基吡咯烷-1-基]-(2s)-2-甲氨基-2-苯基乙烷的工艺
EP3558300B1 (en) * 2016-12-21 2021-11-24 Tioga Pharmaceuticals, Inc. Solid pharmaceutical formulations of asimadoline
EP3932390A1 (en) 2020-07-02 2022-01-05 Dr. August Wolff GmbH & Co. KG Arzneimittel Topical gel formulation containing asimadoline

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4215213A1 (de) * 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide

Also Published As

Publication number Publication date
UA41978C2 (uk) 2001-10-15
CZ287783B6 (en) 2001-02-14
AR004679A1 (es) 1999-03-10
ES2165948T3 (es) 2002-04-01
PL187691B1 (pl) 2004-09-30
HUP9602346A3 (en) 1998-01-28
DK0761650T3 (da) 2002-02-18
TW513407B (en) 2002-12-11
HU226667B1 (en) 2009-06-29
NO307048B1 (no) 2000-01-31
US6060504A (en) 2000-05-09
DE59608050D1 (de) 2001-12-06
EP0761650A1 (de) 1997-03-12
AU6214996A (en) 1997-03-06
PT761650E (pt) 2002-04-29
DE19531464A1 (de) 1997-02-27
JP2009046501A (ja) 2009-03-05
CN1151986A (zh) 1997-06-18
JPH09110830A (ja) 1997-04-28
SK108996A3 (en) 1997-06-04
HU9602346D0 (en) 1996-10-28
JP5023273B2 (ja) 2012-09-12
EP0761650B1 (de) 2001-10-31
ATE207895T1 (de) 2001-11-15
NO963526D0 (no) 1996-08-23
HUP9602346A2 (en) 1997-09-29
KR100436254B1 (ko) 2005-01-25
CN1081631C (zh) 2002-03-27
MX9603606A (es) 1997-03-29
CZ243496A3 (en) 1997-03-12
NO963526L (no) 1997-02-27
PL315799A1 (en) 1997-03-03
AU716615B2 (en) 2000-03-02
JP2012246321A (ja) 2012-12-13
CA2184049A1 (en) 1997-02-27
ZA967200B (en) 1997-03-03
KR970010744A (ko) 1997-03-27
CA2184049C (en) 2007-10-02
RU2174976C2 (ru) 2001-10-20
SK282437B6 (sk) 2002-02-05
SI0761650T1 (en) 2002-04-30

Similar Documents

Publication Publication Date Title
NO2005009I2 (no) Emselex-darifenacin. Iupac-navn: (S)-2-ä1-Ä2-(2,3 -dihydrobenzofuran-5-yl)etylÜ-3-pyrrolidinylü-2,2-difenylacetamid
NO973123L (no) Direkte komprimerbare, höykonsentrerte acetaminofenpreparater
ATE219495T1 (de) Zuckersubstituierte 2-azetidinone, verwendbar als hypocholesterdenische arzneimittel
FI950715A0 (fi) Ytmikromekanisk, symmetrisk tryckskillnadsgivare
BR9603540A (pt) n-metil-n-((1s)-2-((3s)-3-hidróxl-pirrolidin-1-il)etil)-2,2-difenilacetamida
FI905589A0 (fi) N-substituerade derivat av 3r, 4r-etyl -((1-metyl-1h-imidazol-5-yl) metyl)-2-pyrrolidinon.
NO960499D0 (no) Antineurodegenerativt virksomme 10-aminoalifatyldibenz[b,fÅoksepiner
DE69621673D1 (de) (3S)-(6E)-2,3-Dihydrofarnesol enthaltendes Parfüm
DK0874814T3 (da) 25-hydroxy-16-en-26,27-bishomo-cholecalciferoler
ES1037858Y (es) Bloque de notas.
NO982085L (no) Fremgangsmate for rensing av erytropoietiner.
ES1032827Y (es) Instrumento de dibujo perfeccionado.
ES1031926Y (es) Luminaria empotrada, perfeccionada.
ES1030601Y (es) Radiador-convector, perfeccionado.
ES1031891Y (es) Consola perfeccionada.
FI950956A0 (fi) Luftkabel, saosom haengspiralkabel
FI952416A0 (fi) Distributionsanordning foer vaetska, speciellt tvaettvaetska foer vindrutor
FI972988A (fi) Menetelmiä ja farmaseuttisia koostumuksia, joissa käytetään desmetyyliselegiliiniä
ES1030734Y (es) Tapon-llavero, perfeccionado.
ES1031097Y (es) Gorra de visera perfeccionada.
ES1032822Y (es) Grapadora perfeccionada.
ES1031681Y (es) Matraz perfeccionado.
ES1031505Y (es) Estuche de cerillas perfeccionado.
ES1031195Y (es) Lampara generadora de efectos de realidad virtual.
ES1032361Y (es) Sujetador de servilletas perfeccionado.

Legal Events

Date Code Title Description
FB34 Technical and formal requirements: requirement - article 34 of industrial property law
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE COM BASE NOS ARTIGOS 8, 11 E 13 DA LEI 9279/96.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: TIOGA PHARMACEUTICALS, INC. (US)

Free format text: TRANSFERIDO DE: MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG

B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: PARA QUE POSSA SER ACEITA A PETICAO DE MANIFESTACAO OU CONTESTACAO (CODIGO 216) , INPI/RJ 20090002584 DE 12/01/2009, APRESENTE COMPLEMENTACAO DE TAXA NO VALOR DE R$ 110,00.